PTEN and prostate cancer: We treated Pten-null prostate cancer-derived cell lines CAP2 and CAP816 and PTEN-null human prostate cancer cell line PC3 and LNCaP with BAY1082439 to investigate the effects of BAY1082439 on cancer cell-intrinsic properties.